At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
Efinopegdutidedrug
Likely dose
Efinopegdutide 7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment
In Brief
A Phase 1 clinical trial evaluating Efinopegdutide for Non-alcoholic Steatohepatitis and Hepatic Impairment. Completed, enrolled 22 participants across 4 sites.
Detailed Summary
The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Steatohepatitis, Hepatic Impairment
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedSep 2023
Enrollment StartNov 2023
Primary CompletionDec 2024
TodayJul 2026
First PostedSep 25, 2023
Enrollment StartNov 21, 2023
Primary CompletionDec 5, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 2.8 years ago
Interventions
Efinopegdutidedrug
Subcutaneous injection administered at a dose of 7 mg